Study to assess the efficacy and safety of Adjuvant Osimertinib in NSCLC with Uncommon EGFRm

Study identifier:D5161C00024

ClinicalTrials.gov identifier:NCT05546866

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

An Open-label, Prospective, Multi-center, Single-arm Study to assess the efficacy and safety of Adjuvant Osimertinib in Non-small Cell Lung Cancer (NSCLC) with Uncommon Epidermal Growth Factor Receptor Mutations (EGFRm)

Medical condition

Non-small Cell Lung Cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

Osimertinib

Sex

All

Estimated Enrollment

50

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 21 Feb 2023
Estimated Primary Completion Date: 30 Jun 2029
Estimated Study Completion Date: 30 Jun 2029

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 May 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria